Princeton Global Asset Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Princeton Global Asset Management’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,600	Closed	-$24K	–	605
2022 Q1	$24K	Hold	1,600	–	–	0.01%	343
2021 Q4	$28K	Hold	1,600	–	–	0.01%	307
2021 Q3	$34K	Hold	1,600	–	–	0.01%	288
2021 Q2	$32K	Hold	1,600	–	–	0.01%	297
2021 Q1	$47K	Hold	1,600	–	–	0.02%	247
2020 Q4	$48K	Buy	+1,600	New	+$35K	0.02%	246

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PIM

Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return

Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Princeton Global Asset Management's NGM Position: Q2 2022 in Review

Princeton Global Asset Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2022, closing a stake of 1,600 shares — an estimated $24K sold.

Princeton Global Asset Management first reported a position in NGM in Q4 2020 and held it in 6 quarters. The position peaked at $48K in Q4 2020. 123 funds tracked by Wall St. Rank hold NGM as of Q2 2022.

Princeton Global Asset Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Princeton Global Asset Management sold 1,600 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $24K.
Princeton Global Asset Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 6 quarters.
Princeton Global Asset Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $48K in Q4 2020.
123 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Princeton Global Asset Management's 13F filing for Q2 2022, filed 4 Aug 2022.